SLC5A2 and diabetes mellitus: The pleiotropic effects of the SGLT2 inhibitors, such as the improvements in tubulointerstitial ischemia, inflammation, and mitochondrial function, may contribute to improved kidney outcomes in patients with diabetes or CKD with normoalbuminuria [57,58].